trending Market Intelligence /marketintelligence/en/news-insights/trending/wTSrXE06pe-5PZv6eIKO7g2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

CytomX Therapeutics chairman to resign; replacement named

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


CytomX Therapeutics chairman to resign; replacement named

CytomX Therapeutics Inc. said Hoyoung Huh would step down as chairman, effective Dec. 31.

The company appointed President and CEO Sean McCarthy to replace Hoyoung as chairman and James Meyers as a board member.

Meyers serves as a director at Arbutus Biopharma Corp., a public biopharmaceutical company. In addition, he was executive vice president of worldwide commercial operations at Gilead Sciences Inc.

South San Francisco, Calif.-based CytomX Therapeutics operates as an oncology-focused biopharmaceutical company.